Short-term Intensive Lifestyle Therapy in a Worksite Setting Improves Cardiometabolic Health in People With Obesity.
Pritikin diet
diabetes
low-fat diet
metabolic syndrome
Journal
Journal of the Endocrine Society
ISSN: 2472-1972
Titre abrégé: J Endocr Soc
Pays: United States
ID NLM: 101697997
Informations de publication
Date de publication:
05 May 2023
05 May 2023
Historique:
received:
27
02
2023
medline:
8
5
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
epublish
Résumé
The Pritikin Program, which provides intensive lifestyle therapy, has been shown to improve cardiometabolic outcomes when provided as a residential program. The purpose of the present study was to conduct a short-term, randomized, controlled trial to evaluate the feasibility and clinical efficacy of treatment with the Pritikin Program in an outpatient worksite setting. Cardiometabolic outcomes were evaluated in people with overweight/obesity and ≥2 metabolic abnormalities (high triglycerides, low high-density lipoprotein (HDL) cholesterol, high blood pressure, HbA1c > 5.7%), before and after they were randomized to 6 weeks of standard care (n = 26) or intensive lifestyle therapy, based on the Pritikin Program (n = 28). Participants in the lifestyle intervention group were provided all food as packed-out meals and participated in group nutrition, behavioral education, cooking classes, and exercise sessions 3 times per week at a worksite location. Compared with standard care, intensive lifestyle therapy decreased body weight (-5.0% vs -0.5%), HbA1c (-15.5% vs +2.3%), plasma total cholesterol (-9.8% vs +7.7%), low-density lipoprotein cholesterol (-10.3% vs +9.3%) and triglyceride (-21.7% vs +3.0%) concentrations, and systolic blood pressure (-7.0% vs 0%) (all This study demonstrates the feasibility and clinical effectiveness of short-term, intensive outpatient lifestyle therapy in people with overweight/obesity and increased risk of coronary heart disease when all food is provided and the intervention is conducted at a convenient worksite setting.
Identifiants
pubmed: 37153109
doi: 10.1210/jendso/bvad048
pii: bvad048
pmc: PMC10161138
doi:
Types de publication
Journal Article
Langues
eng
Pagination
bvad048Subventions
Organisme : NIDDK NIH HHS
ID : P30 DK020579
Pays : United States
Informations de copyright
© The Author(s) 2023. Published by Oxford University Press on behalf of the Endocrine Society.
Références
N Engl J Med. 1990 Oct 18;323(16):1142-3
pubmed: 2215586
Obes Res. 2005 Nov;13(11):1849-63
pubmed: 16339115
JAMA. 2013 Dec 11;310(22):2416-25
pubmed: 24189773
Circulation. 2002 Nov 12;106(20):2530-2
pubmed: 12427646
N Engl J Med. 1985 Oct 10;313(15):958-9
pubmed: 4033732
Diabetes Care. 1983 May-Jun;6(3):268-73
pubmed: 6307614
Circulation. 1995 Jul 15;92(2):197-204
pubmed: 7600651
Prog Cardiovasc Dis. 2018 Jul - Aug;61(2):246-252
pubmed: 29890171
N Engl J Med. 2003 May 22;348(21):2082-90
pubmed: 12761365
Diabetes Care. 1993 Sep;16(9):1313-4
pubmed: 8404444
Am J Clin Nutr. 2007 Feb;85(2):346-54
pubmed: 17284728
Clin Chem. 2018 Jan;64(1):118-129
pubmed: 29054924
Arch Intern Med. 1991 Jul;151(7):1389-94
pubmed: 2064490
Gastroenterology. 2002 Sep;123(3):882-932
pubmed: 12198715
PLoS One. 2014 Mar 25;9(3):e92458
pubmed: 24667212
Obesity (Silver Spring). 2014 Jul;22(7):1608-16
pubmed: 24771618
Clin Cornerstone. 2007;8(3):29-37
pubmed: 18452840
J Cardiometab Syndr. 2006 Fall;1(5):308-12
pubmed: 17679787
J Appl Physiol (1985). 2005 Jan;98(1):3-30
pubmed: 15591300
Ther Adv Chronic Dis. 2014 May;5(3):135-48
pubmed: 24790728